Correlation between Fib 4scoreandHematological adverseevents in patientswithchronichepatitis Cvirus infection undertreatment byInterferon basedTripletherapy

Abstract

Chronic hepatitis C is a major cause of cirrhosis, end stage liver disease and hepatocellular carcinoma. The population of Egypt has a heavy burden with HCV. The primary aim of anti-HCV therapy is permanent eradication of the virus or a sustained viral response there by reducing the risk of progression to end-stage liver disease and improving quality of life. In Egypt, Patients infected with HCV genotype 4 and are eligible to IFN therapy can be treated with a combination of weekly PEGylated IFN-α, daily weight-based ribavirin (1000 mg in patients <75 kg or 1200 mg in patients ≥75 kg,), and daily sofosbuvir (400 mg) for 12 weeks). However, these drugs together with HCV itself have been reported to cause multiple hematological side effects e.g. anemia, neutropenia and thrombocytopenia It has been reported that hematologic adverse effects during treatment by Peg INF and RBV are more common in patients with more advanced degree of fibrosis, in addition fibrosis score may be used as Predictor of response of HCV infected patients to therapy. Aim of the work: Assessment of relation between degree of fibrosis assessed by Fib4 and both response to treatment and hematological adverse effects related to treatment. CONCLUSION: Our research found that there is no association of degree of fibrosis assessed by Fib4 and SVR, but hematological adverse effects e.g. anemia, leucopenia, and neutropenia were common in patients with high degree of fibrosis assessed by Fib4